IceCure Medical Ltd. announced it has received a Notice of Allowance from the United States Patent and Trademark Office for its patent application titled "Cryogen Flow Control." This innovation is designed to enhance the efficiency of cryoablation procedures by utilizing sensor data to regulate cryogen flow, ensuring precise temperature control for improved treatment effectiveness. The patent, once granted, will be valid until 2045. This development represents a significant step in expanding IceCure's intellectual property assets and advancing its cryoablation technology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.